Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 107

    USFDA issues warning letter to Indoco Remedies for Goa plant

    USFDA issues warning letter to Indoco Remedies for Goa plant

    Medical Dialogues Bureau16 July 2019 11:39 AM IST
    The facility had received six observations in Form 483s and was classified as Official Action Indicated in March. Indoco Remedies responded to these...
    Natco Pharma gets zero USFDA observations for Chennai facility

    Natco Pharma gets zero USFDA observations for Chennai facility

    Medical Dialogues Bureau16 July 2019 9:30 AM IST
    Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical...
    GSK drug Zejula helps ovarian cancer patients live longer in late-stage study

    GSK drug Zejula helps ovarian cancer patients live longer in late-stage study

    Medical Dialogues Bureau16 July 2019 9:26 AM IST
    GSK bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian...
    AstraZeneca Farxiga fails to win USFDA approval for Type-1 diabetes

    AstraZeneca Farxiga fails to win USFDA approval for Type-1 diabetes

    Medical Dialogues Bureau16 July 2019 9:25 AM IST
    AstraZeneca said USFDA issued a complete response letter, declining its application for using the drug in patients with Type-1 diabetes where insulin...
    Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy

    Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy

    Medical Dialogues Bureau16 July 2019 9:15 AM IST
    The total transaction could amount up to EUR 325 million and is comprised of upfront payment as well as contingent clinical, development and...
    Sun Pharma unveils Ezallor Sprinkle capsules for treating lipid disorder in US

    Sun Pharma unveils Ezallor Sprinkle capsules for treating lipid disorder in US

    Farhat Nasim15 July 2019 2:40 PM IST
    Ezallor Sprinkle (rosuvastatin) capsules are indicated for three types of lipid disorders in conjunction with diet in adults, Sun Pharma said in a...
    GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg

    GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg

    Medical Dialogues Bureau15 July 2019 2:29 PM IST
    The appointment of Jonathan Symonds, currently the deputy chairman at HSBC Holdings Plc, still needs to be finalized and is subject to approval from...
    Lupin to focus on launch of biosimilar, inhalation product in US this fiscal

    Lupin to focus on launch of biosimilar, inhalation product in US this fiscal

    Medical Dialogues Bureau15 July 2019 9:45 AM IST
    Coupling this with the building of Solosec brand in the US, NaMuscla in Europe and Bipresso in Japan will help Lupin drive sustainable growth, they...
    Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

    Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

    Medical Dialogues Bureau15 July 2019 9:30 AM IST
    The deal is the largest Gilead has executed since new Chief Executive Officer Dan O'Day took the reins in March as he attempts to bolster the San...
    First-in-human Trial: Cyxone begins Phase 1 trial with T20K for treatment of multiple sclerosis

    First-in-human Trial: Cyxone begins Phase 1 trial with T20K for treatment of multiple sclerosis

    Medical Dialogues Bureau15 July 2019 9:00 AM IST
    Cyxone's application to start a first-in-human, phase I, trial with their prophylactic drug candidate T20K targeting multiple sclerosis (MS) has been...
    Aurobindo Pharma in focus on launch of generic version of Sensipar tablets in US

    Aurobindo Pharma in focus on launch of generic version of Sensipar tablets in US

    Farhat Nasim14 July 2019 10:15 AM IST
    Aurobindo Pharma's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet...
    Laurus Labs gets no USFDA observations for Vizag unit

    Laurus Labs gets no USFDA observations for Vizag unit

    Medical Dialogues Bureau14 July 2019 10:00 AM IST
    The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483...
    PrevNext

    Popular Stories

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    China offers tariff exemptions on US medical equipment amid virus outbreak

    China offers tariff exemptions on US medical equipment amid virus outbreak

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    BA/BE study applications have to be processed in 15 days: CDSCO

    BA/BE study applications have to be processed in 15 days: CDSCO

    FDA warns about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical Information Central Stations and Telemetry Servers

    FDA warns about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical...

    Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    OncoStem Diagnostics named

    OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and...

    Drug marketers to take onus for quality of drugs, regulatory compliance: Health Ministry Gazette

    Drug marketers to take onus for quality of drugs, regulatory compliance: Health Ministry Gazette

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok